Inventurus Knowledge Solutions Ltd (IKS) is currently trading at 1,789.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Inventurus Knowledge Solutions Limited (IKS Health) is a tech-enabled healthcare provider enablement platform that outsources and automates administrative and clinical workflows for US healthcare providers, spanning pre-visit, peri-visit and post-visit features across ambulatory and acute settings and serving hundreds of enterprise customers with a mix of people and AI-led solutions. Q3 FY26 delivered strong operating performance: INR 8,150 million revenue (24% YoY), adjusted EBITDA margin near mid-30s and adjusted PAT growth near 48% YoY, reflecting faster-than-market revenue expansion and a margin-rich business model driven by AI-led automation and accelerated AQuity integration into consolidated results. IKS has moved to an AI-native, agentic orchestration approach—launching Scribble Now, autonomous coding in select specialties and multi-agent workflows across patient access and documentation—demonstrating measurable non-linearity between revenue growth and headcount expansion, with headcount essentially flat versus substantial revenue uplift. Strategically the business is shifting upstream to outcome-oriented economics via net economic value-add (NEVA) guarantees: the Palomar 15-year engagement (NEVA advance) generated $3 million in the first year, substantiating the company’s ability to monetize outcomes while preserving stickiness and opening a second pool of economics beyond usage fees. Cash generation is robust and improving: OCF and FCF surged nearly 50% YoY in 9M FY26, net debt fell meaningfully to INR 3,220 million as of Dec 31, 2025, and management flagged continued prioritization of deleveraging, selective inorganic opportunities and reinvestment into R&D and go-to-market acceleration.

Over the past 52 weeks, Inventurus Knowledge Solutions Ltd has traded between a low of ₹1,262.35 and a high of ₹1,933.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Inventurus Knowledge Solutions Ltd has a market capitalization of approximately 29,805.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Inventurus Knowledge Solutions Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.02 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 29,805.02 Cr, Inventurus Knowledge Solutions Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Inventurus Knowledge Solutions Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Inventurus Knowledge Solutions Ltd is 39.02. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

IKS Health reported consolidated revenue from operations of ₹893.63 crore and consolidated net profit of ₹194 crore for the quarter ended June 30, 2026.

The stock symbol is INVU, and the company trades on the National Stock Exchange of India.

Net sales were reported at ₹857.65 crore for the March 2026 quarter, up 18.47% from ₹723.96 crore in March 2025.

Standalone net sales were ₹412.69 crore in the quarter ended March 2026, up 42.13% from ₹290.37 crore in March 2025.